Literature DB >> 19279568

Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.

Mei-Chuan Ko1, James H Woods, William E Fantegrossi, Chad M Galuska, Jürgen Wichmann, Eric P Prinssen.   

Abstract

Behavioral effects of a nonpeptidic NOP (nociceptin/orphanin FQ Peptide) receptor agonist, Ro 64-6198, have not been studied in primate species. The aim of the study was to verify the receptor mechanism underlying the behavioral effects of Ro 64-6198 and to systematically compare behavioral effects of Ro 64-6198 with those of a mu-opioid receptor agonist, alfentanil, in monkeys. Both Ro 64-6198 (0.001-0.06 mg/kg, s.c.) and alfentanil (0.001-0.06 mg/kg, s.c.) produced antinociception against an acute noxious stimulus (50 degrees C water) and capsaicin-induced allodynia. An NOP receptor antagonist, J-113397 (0.01-0.1 mg/kg, s.c.), dose-dependently produced rightward shifts of the dose-response curve of Ro 64-6198-induced antinociception. The apparent pA(2) value of J-113397 was 8.0. Antagonist studies using J-113397 and naltrexone revealed that Ro 64-6198 produced NOP receptor-mediated antinociception independent of mu-opioid receptors. In addition, alfentanil dose-dependently produced respiratory depression and itch/scratching responses, but antinociceptive doses of Ro 64-6198 did not produce such effects. More important, Ro 64-6198 did not produce reinforcing effects comparable with those of alfentanil, cocaine, or methohexital under self-administration procedures in monkeys. These results provide the first functional evidence that the activation of NOP receptors produces antinociception without reinforcing effects in primates. Non-peptidic NOP receptor agonists may have therapeutic value as novel analgesics without abuse liability in humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19279568      PMCID: PMC2804925          DOI: 10.1038/npp.2009.33

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  47 in total

1.  Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397).

Authors:  H Kawamoto; S Ozaki; Y Itoh; M Miyaji; S Arai; H Nakashima; T Kato; H Ohta; Y Iwasawa
Journal:  J Med Chem       Date:  1999-12-16       Impact factor: 7.446

2.  Inhibition of striatal and retinal dopamine release via nociceptin/orphanin FQ receptors.

Authors:  K Flau; A Redmer; S Liedtke; M Kathmann; E Schlicker
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

3.  Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia.

Authors:  J B Davis; J Gray; M J Gunthorpe; J P Hatcher; P T Davey; P Overend; M H Harries; J Latcham; C Clapham; K Atkinson; S A Hughes; K Rance; E Grau; A J Harper; P L Pugh; D C Rogers; S Bingham; A Randall; S A Sheardown
Journal:  Nature       Date:  2000-05-11       Impact factor: 49.962

4.  Orphanin FQ inhibits capsaicin-induced thermal nociception in monkeys by activation of peripheral ORL1 receptors.

Authors:  M C H Ko; N N Naughton; J R Traynor; M S Song; J H Woods; K C Rice; A T McKnight
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

5.  Synthesis of (1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties.

Authors:  J Wichmann; G Adam; S Röver; M Hennig; M Scalone; A M Cesura; F M Dautzenberg; F Jenck
Journal:  Eur J Med Chem       Date:  2000-09       Impact factor: 6.514

6.  A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat.

Authors:  F Jenck; J Wichmann; F M Dautzenberg; J L Moreau; A M Ouagazzal; J R Martin; K Lundstrom; A M Cesura; S M Poli; S Roever; S Kolczewski; G Adam; G Kilpatrick
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

7.  Relative reinforcing effects of three opioids with different durations of action.

Authors:  M C Ko; J Terner; S Hursh; J H Woods; G Winger
Journal:  J Pharmacol Exp Ther       Date:  2002-05       Impact factor: 4.030

8.  Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys.

Authors:  Mei-Chuan Ko; Norah N Naughton
Journal:  J Pain       Date:  2009-02-23       Impact factor: 5.820

9.  Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy?

Authors:  Hanns Ulrich Zeilhofer; Girolamo Calò
Journal:  J Pharmacol Exp Ther       Date:  2003-04-29       Impact factor: 4.030

10.  Autoradiographic localization of (125)i[Tyr(14)] nociceptin/orphanin FQ binding sites in macaque primate CNS.

Authors:  K E Bridge; A Wainwright; K Reilly; K R Oliver
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

View more
  46 in total

Review 1.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

Review 2.  Nociceptin and the nociceptin receptor in learning and memory.

Authors:  Raül Andero
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-02-24       Impact factor: 5.067

3.  Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.

Authors:  Devki D Sukhtankar; Nurulain T Zaveri; Stephen M Husbands; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2013-05-07       Impact factor: 4.030

4.  Activation of nociceptin/orphanin FQ peptide receptors disrupts visual but not auditory sensorimotor gating in BALB/cByJ mice: comparison to dopamine receptor agonists.

Authors:  Aurelia Ces; David Reiss; Ondine Walter; Jürgen Wichmann; Eric P Prinssen; Brigitte L Kieffer; Abdel-Mouttalib Ouagazzal
Journal:  Neuropsychopharmacology       Date:  2011-08-31       Impact factor: 7.853

Review 5.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

6.  BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates.

Authors:  Norikazu Kiguchi; Huiping Ding; Gerta Cami-Kobeci; Devki D Sukhtankar; Paul W Czoty; Heather B DeLoid; Fang-Chi Hsu; Lawrence Toll; Stephen M Husbands; Mei-Chuan Ko
Journal:  Br J Anaesth       Date:  2019-03-01       Impact factor: 9.166

7.  A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.

Authors:  Huiping Ding; Norikazu Kiguchi; Dennis Yasuda; Pankaj R Daga; Willma E Polgar; James J Lu; Paul W Czoty; Shiroh Kishioka; Nurulain T Zaveri; Mei-Chuan Ko
Journal:  Sci Transl Med       Date:  2018-08-29       Impact factor: 17.956

8.  Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.

Authors:  Lawrence Toll; Taline V Khroyan; Willma E Polgar; Faming Jiang; Cris Olsen; Nurulain T Zaveri
Journal:  J Pharmacol Exp Ther       Date:  2009-09-22       Impact factor: 4.030

Review 9.  The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.

Authors:  Ann P Lin; Mei-Chuan Ko
Journal:  ACS Chem Neurosci       Date:  2012-11-06       Impact factor: 4.418

Review 10.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.